Calidi Biotherapeutics
CLDI
23 hedge funds and large institutions have $2.85M invested in Calidi Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
92% more funds holding
Funds holding: 12 → 23 (+11)
0.02% more ownership
Funds ownership: 0.02% → 0.05% (+0.02%)
19% less capital invested
Capital invested by funds: $3.54M → $2.85M (-$685K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$229K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$229K |
| 3 |
GL
Governors Lane
New York
|
+$212K |
| 4 |
SAMC
Spectrum Asset Management (California)
Newport Beach,
California
|
+$186K |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$416K |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$324K |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$30.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$332 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
26
Highbridge Capital Management
New York
| – | -$416K | -1,042 | Closed |
|
|
27
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
| – | -$30.5K | -76 | Closed |
|
|
28
Bank of America
Charlotte,
North Carolina
| – | -$332 | -1 | Closed |
|
CLDI Hedge Fund Activity: Q4 2023 in Review
23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q4 2023, worth a combined $2.85M — down 19% from $3.54M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CLDI positions and 3 closed out — a net gain of 11 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $229K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $416K sold.
- 23 institutional investors held Calidi Biotherapeutics (CLDI) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $2.85M of Calidi Biotherapeutics stock for Q4 2023, down 19% quarter-over-quarter.
- 14 funds opened new Calidi Biotherapeutics positions in Q4 2023 and 3 closed out, a net change of +11 holders.
- The largest Calidi Biotherapeutics buyer in Q4 2023 was Millennium Management, an estimated $229K added.
- The largest Calidi Biotherapeutics seller in Q4 2023 was Highbridge Capital Management, an estimated $416K sold.
Based on aggregated 13F filings for Q4 2023.